Products for Research Use Only
RegisterLogin

Seclidemstat

CAT: 0804-HY-103713-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-103713-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM) . Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma[1][2].
CAS Number
1423715-37-0
Product Name Alternative
SP-2577
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Histone Demethylase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Seclidemstat.html
Purity
99.77
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C)
Smiles
O=C(N/N=C(C1=CC(Cl)=CC=C1O)\C)C2=CC=CC(S(=O)(N3CCN(C)CC3)=O)=C2
Molecular Formula
C20H23ClN4O4S
Molecular Weight
450.94
Precautions
H302, H315, H319, H335
References & Citations
[1]Dai XJ, et al. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1 [published correction appears in J Med Chem. 2021 May 13;64 (9) :6410-6411]. J Med Chem. 2021;64 (5) :2466-2488. |[2]Soldi R, et al. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS One. 2020;15 (7) :e0235705. Published 2020 Jul 10.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
KDM1/LSD1
Citation 01
ACS Pharmacol Transl Sci. 2021 Nov 12;4 (6) :1818-1834.|Biochem Biophys Res Commun. 2025 Jan 27:750:151330.|bioRxiv. 2020 May.|Boston University. 2025.|Cancer Lett. 2024 Aug 21:600:217182.|Clin Exp Med. 2025 Nov 25;26 (1) :33.|Mol Cancer. 2025 Apr 23;24 (1) :122.|Mol Divers. 2024 Dec;28 (6) :4403-4424.|Nat Cell Biol. 2022 Mar;24 (3) :373-383.|bioRxiv. 2024 October 29.|Clin Exp Med. 2025 Nov 25;26 (1) :33.|Indiana University. 2025.

Alternative Products

CatalogName
BA4781-5.1Seclidemstat
A19730-500Seclidemstat 500mg
A19730-200Seclidemstat 200mg
T39439-01Seclidemstat mesylate
A19730-100Seclidemstat 100mg
S6722-25mgSeclidemstat (SP-2577)
A19730-50Seclidemstat 50mg
A19730-25Seclidemstat 25mg
A19730-10Seclidemstat 10mg
A19730-5Seclidemstat 5mg

Popular Products